La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

MEI Pharma Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jay File

Amministratore delegato

US$655.7k

Compenso totale

Percentuale dello stipendio del CEO	68.6%
Mandato del CEO	1.1yrs
Proprietà del CEO	n/a
Durata media del management	2yrs
Durata media del Consiglio di amministrazione	3.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jay File rispetto agli utili di MEI Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	US$656k	US$450k	US$18m

Compensazione vs Mercato: La retribuzione totale di Jay ($USD 655.65K ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 364.87K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Jay con le performance aziendali.

AMMINISTRATORE DELEGATO

Jay File (54 yo)

1.1yrs

Mandato

US$655,650

Compensazione

Mr. Justin J. File, also known as Jay, serves as CFO & Corporate Secretary at MEI Pharma, Inc. since August 01, 2023 and serves as its Acting Chief Executive Officer from August 01, 2024. He had been an Ex...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Justin File	Acting CEO	1.1yrs	US$655.65k	Nessun dato
Yomara Gomez-Naiden	Senior Vice President of Operations & Quality	1.2yrs	Nessun dato	Nessun dato
Nicole Iida	Vice President of Legal Affairs	1.7yrs	Nessun dato	Nessun dato
Anne Frese	Chief People Officer	2.3yrs	Nessun dato	Nessun dato
Robert Mass	Strategic Advisor	13.3yrs	US$755.98k	Nessun dato
David Walsey	Senior Vice President of Corporate Affairs	3.3yrs	Nessun dato	Nessun dato

2.0yrs

Durata media

Gestione esperta: Il team dirigenziale di 0JW9 non è considerato esperto (durata media 1.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Frederick Driscoll	Independent Chairperson	6.6yrs	US$117.20k	0.028% $ 5.4k
Nicholas Glover	Independent Non-Executive Director	11.3yrs	US$122.78k	0% $ 0
Thomas Reynolds	Independent Non-Executive Director	11.6yrs	US$115.28k	0.0075% $ 1.4k
Steven Wood	Independent Non-Executive Director	less than a year	US$112.40k	0.14% $ 26.8k
James Flynn	Independent Director	less than a year	US$114.07k	0.12% $ 22.6k
Taheer Datoo	Director	less than a year	US$68.06k	Nessun dato

3.8yrs

Durata media

49yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0JW9 sono considerati esperti (durata media dell'incarico 3.7 anni).

MEI Pharma Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Recent updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings released: US$2.32 loss per share (vs US$1.31 loss in 3Q 2022)

Insufficient new directors

Insufficient new directors

MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors

Mei Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. Announces Board Changes

Full year 2022 earnings released: US$0.44 loss per share (vs US$0.37 loss in FY 2021)

MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma, Inc. announced delayed 10-Q filing

MEI Pharma Receives Non-Compliance Notice from Nasdaq

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MEI Pharma, Inc. Announces New Key Executive Appointments

No longer forecast to breakeven

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Forecast to breakeven in 2024

Forecast to breakeven in 2024

MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 3000E Value Index

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

Third quarter 2021 earnings released: US$0.28 loss per share (vs US$0.041 loss in 3Q 2020)

Independent Non-Executive Director recently sold US$101k worth of stock

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020)

Revenue beats expectations

MEI Pharma, Inc. Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media